A recent study indicated that patients with MET-amplified NSCLCs with concurrent high PD-L1 expression had a decreased tumour response to anti-PD-1 immunotherapy [33], and neoadjuvant targeted therapy with MET-TKIs might be a better choice for locally advanced MET-amplified NSCLCs. This evidence concerns the gene CD274 and neoplasm.